Please Wait...

How Time, Quality & Cost Metrics Affect Clinical Trials and Programs

There are principally three characteristics, or metrics, we can use to measure any major process:  TIME. QUALITY.  COST.  The challenge is that these three are in competition. Nowhere is this more apparent than in the design and implementation of clinical trials and clinical programs.  There are three characteristics but you can only emphasize 2!

In the current environment we have seen COST become the main driver throughout the pharmaceutical and biotech industry.  However, this usually works at the long-term penalty of quality and or time.  A recent case in point was a small company that asked us to handle the imaging portion of the clinical trial.  Everything was pared down to yield the most apparent “cost effective solution” at the outset.  We are now half way through the trial and key imaging end points need to be delivered and safety evaluations are being considered.  Suddenly the need for quality has come to the forefront, particularly as the data will be going to a regulatory agency.  However, this shift has caused increases in scope of work that may be exceed the original budget and possibly be higher than necessary due to the amount of rework, which would have been negated if the need for quality had been more carefully considered at the start.  Furthermore, time is of the essence, but due to prior decisions it has to take second place behind the quality issues.

Not to be outdone, the familiar big pharma code words “looking at the most cost effective solutions” really means “drastically reducing our internal budgets and vendor budgets for the same level of work”. It will be interesting to see if this strategy will truly produce more products brought to market cost effectively or whether quality and time effects will eventually show through in this highly regulated world.  In a different arena – cars manufacturing – we have seen this play out to a dramatic effect with Toyota.  For many years Toyota has built a reputation on quality and reliability.  “Everyone knew” that a Toyota would last for years.  Then Toyota shifted from their primary metric and elected to become the Number One car manufacturer in the world.  Cost and time took priority over quality, and long term, we now all know the results.

The pharmaceutical industry lives in a far more regulated world, so I have less concern about the potential “Toyota effect” – since the FDA and other regulatory bodies help ensure that safety and quality are paramount.  However drug development will take even longer if quality is not maintained.  Innovative technology solutions will not be developed nor implemented any sooner under a “keep cost low” mantra.  The industry desperately needs to reduce the cost of drug development, but rather than just slash budgets, identification of high impact new technologies should be evaluated.  If implemented correctly, higher quality systems can be implemented which over the long term should result in cost savings and efficiency.   This only works if the principal metrics are kept in balance.

I have recently heard it stated by a consultant at a pharma company that “we are going to cut budgets by 10% each year while increasing output” With that metric at the forefront, we will all do more and more for less and less until we can do everything for practically nothing!



Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

What's next from Bioclinica? Hear if first during #PCTrials Europe next week in Amsterdam!
bioclinica (6 hours ago)
Join Bioclinica's Justin Hunt on Nov. 28 in a live webinar! Find out how to overcome common hurdles in CTMS impleme…
bioclinica (Yesterday)
Another CRO seeing big gains in the sites payments process! Access the Case Study here
bioclinica (Yesterday)
Great advice from our Dir. Cardiovascular Imaging on quality imaging acquisitions & assessments in clin trials.
bioclinica (2 days ago)
Almost here! #PCTrials Pre-arrange a meeting w @bioclinica Drop by & s/w David Kiger & Mike Lange. Mike will give a…
bioclinica (2 days ago)
Almost here! #PCTrials Pre-arrange a meeting w @bioclinica Drop by & s/w David Kiger & Mike Lange. Mike will giv…
bioclinica (2 days ago)

Latest Blogs:

Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen
Congressman Meehan and Bioclinica CEO John Hubbard at recent visit to Bioclinica's Audubon offices